Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
Ensysce Biosciences (NASDAQ:ENSC) has released two video segments from its symposium at the International Association for the Study of Pain (IASP) 2024 World Congress in Amsterdam. The symposium focused on opioid use worldwide and Ensysce's innovative opioid drug products for severe pain relief. Dr. William Schmidt, CMO, explained the government support received from NIH and FDA, and highlighted how PF614, Ensysce's lead agent, aligns with ideal pain product characteristics. CEO Dr. Lynn Kirkpatrick emphasized the company's novel approach using TAAP and MPAR platforms to develop opioids with reduced abuse and overdose potential. Ensysce plans to begin a Phase 3 pivotal trial soon and explore PF614's use in cancer treatment, aiming to provide prescribers with new options for effective patient care.
Ensysce Biosciences (NASDAQ:ENSC) ha rilasciato due segmenti video dal suo simposio presso il Congresso Mondiale 2024 dell'International Association for the Study of Pain (IASP) ad Amsterdam. Il simposio si è concentrato sull'uso degli oppioidi a livello mondiale e sui prodotti innovativi di oppioidi di Ensysce per il sollievo dal dolore severo. Il Dr. William Schmidt, CMO, ha spiegato il supporto governativo ricevuto dal NIH e dalla FDA, e ha messo in evidenza come PF614, il principale agente di Ensysce, si allinei alle caratteristiche ideali dei prodotti per il dolore. Il CEO Dr. Lynn Kirkpatrick ha sottolineato l'approccio innovativo dell'azienda nell'utilizzo delle piattaforme TAAP e MPAR per sviluppare oppioidi con un potenziale ridotto di abuso e overdose. Ensysce prevede di avviare presto un trial pivotale di Fase 3 ed esplorare l'uso di PF614 nel trattamento del cancro, con l'obiettivo di fornire ai medici nuove opzioni per una cura efficace dei pazienti.
Ensysce Biosciences (NASDAQ:ENSC) ha lanzado dos segmentos de video desde su simposio en el Congreso Mundial 2024 de la Asociación Internacional para el Estudio del Dolor (IASP) en Ámsterdam. El simposio se centró en el uso de opioides en todo el mundo y en los productos innovadores de opioides de Ensysce para el alivio del dolor severo. El Dr. William Schmidt, CMO, explicó el apoyo gubernamental recibido del NIH y la FDA, y destacó cómo PF614, el agente principal de Ensysce, se alinea con las características ideales de los productos para el dolor. La CEO, la Dra. Lynn Kirkpatrick, enfatizó el enfoque novedoso de la empresa mediante el uso de las plataformas TAAP y MPAR para desarrollar opioides con un menor potencial de abuso y sobredosis. Ensysce planea comenzar pronto un ensayo pivotal de Fase 3 y explorar el uso de PF614 en el tratamiento del cáncer, con el objetivo de ofrecer a los prescriptores nuevas opciones para el cuidado eficaz de los pacientes.
Ensysce Biosciences (NASDAQ:ENSC)는 암스테르담에서 열린 2024년 국제통증학회(IASP) 세계대회의 심포지엄에서 두 개의 비디오 세그먼트를 공개했습니다. 이 심포지엄은 전 세계 오피오이드 사용과 심한 통증 완화를 위한 Ensysce의 혁신적인 오피오이드 약물 제품에 초점을 맞추었습니다. CMO인 윌리엄 슈미트 박사는 NIH와 FDA에서 받은 정부 지원을 설명하며, Ensysce의 주요 물질인 PF614가 이상적인 통증 제품 특성과 어떻게 일치하는지를 강조했습니다. CEO인 린 커크패트릭 박사는 남용 및 과다 복용 가능성을 줄인 오피오이드를 개발하기 위해 TAAP 및 MPAR 플랫폼을 사용하는 회사의 혁신적인 접근 방식을 강조했습니다. Ensysce는 곧 3상 주요 임상시험을 시작하고 PF614의 암 치료 사용을 탐색할 계획이며, 효과적인 환자 치료를 위한 새로운 옵션을 처방자에게 제공하는 것을 목표로 하고 있습니다.
Ensysce Biosciences (NASDAQ:ENSC) a publié deux segments vidéo de son symposium lors du Congrès mondial 2024 de l'International Association for the Study of Pain (IASP) à Amsterdam. Le symposium a porté sur l'utilisation des opioïdes dans le monde et sur les produits innovants d'opiodes d'Ensysce pour soulager les douleurs sévères. Le Dr William Schmidt, CMO, a expliqué le soutien gouvernemental reçu du NIH et de la FDA, et a souligné comment PF614, le principal agent d'Ensysce, correspond aux caractéristiques idéales des produits antidouleur. La PDG, le Dr Lynn Kirkpatrick, a souligné l'approche novatrice de l'entreprise en utilisant les plateformes TAAP et MPAR pour développer des opioïdes avec un potentiel réduit d'abus et de surdose. Ensysce prévoit de commencer bientôt un essai pivot de phase 3 et d'explorer l'utilisation de PF614 dans le traitement du cancer, visant à offrir aux prescripteurs de nouvelles options pour des soins efficaces aux patients.
Ensysce Biosciences (NASDAQ:ENSC) hat zwei Videosegmente von seinem Symposium beim 2024 World Congress der International Association for the Study of Pain (IASP) in Amsterdam veröffentlicht. Das Symposium konzentrierte sich auf den weltweiten Gebrauch von Opioiden und die innovativen Opioid-Arzneimittelprodukte von Ensysce zur Linderung von starkem Schmerz. Dr. William Schmidt, CMO, erklärte die staatliche Unterstützung, die von NIH und FDA erhalten wurde, und hob hervor, wie PF614, der Hauptbestandteil von Ensysce, mit den idealen Eigenschaften von Schmerzprodukten übereinstimmt. CEO Dr. Lynn Kirkpatrick betonte den neuartigen Ansatz des Unternehmens, mithilfe der TAAP- und MPAR-Plattformen Opioide mit reduziertem Missbrauchs- und Überdosierungsrisiko zu entwickeln. Ensysce plant, bald eine Phase-3 entscheidende Studie zu beginnen und die Verwendung von PF614 in der Krebsbehandlung zu erforschen, mit dem Ziel, den Verschreibern neue Optionen für eine effektive Patientenversorgung zu bieten.
- Ensysce's lead agent PF614 aligns with characteristics of an ideal pain product
- Company plans to begin Phase 3 pivotal trial for PF614
- Exploring potential use of PF614 in cancer treatment
- Received government support from NIH and FDA for drug development
- None.
Insights
The symposium at the IASP World Congress on Pain represents a significant platform for Ensysce Biosciences to showcase their innovative opioid products, PF614 and PF614-MPAR. These novel drugs, utilizing TAAP and MPAR platforms, aim to address the critical need for effective pain management with reduced abuse and overdose potential. The company's engagement with international pain experts suggests a strategic move towards global market positioning.
The announcement of an upcoming Phase 3 pivotal trial for PF614 is a important milestone, indicating the product's advancement in the clinical pipeline. Additionally, exploring PF614's potential in cancer pain management could significantly expand its market reach. However, investors should note that while government support from NIH and FDA is promising, the path to regulatory approval and market acceptance for novel opioids remains challenging due to stringent safety requirements and existing stigma.
Ensysce's approach to developing abuse-deterrent opioids addresses a critical need in pain management. The company's TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) technologies represent innovative solutions to the opioid crisis. However, it's important to note that the opioid market is highly competitive and heavily scrutinized.
The company's focus on severe pain, including post-surgical and cancer pain, targets high-need areas where alternative treatments are The international symposium exposure is valuable for building credibility and potentially expanding into global markets. Investors should watch for the outcomes of the upcoming Phase 3 trial, as success could significantly boost Ensysce's market position. However, be aware that regulatory hurdles for new opioid products are exceptionally high and market adoption may face resistance from prescribers cautious about new opioid formulations.
~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~
SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8th symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium emphasized opioid use worldwide, the current landscape for treating severe pain, including post-surgical and cancer pain treatment, and discussed Ensysce's innovative new class of opioid drug products.
The discussion allowed for feedback and questions from experts in attendance facilitating proper introduction and explanation of the differentiated Ensysce approach and the possible needs from countries outside the United States for these unique opioids.
Two short videos from the session have been posted to Media / Science Center page on the Company's website. Dr. William Schmidt, Chief Medical Officer of Ensysce explains the government support the Company has received from both the National Institutes of Health and the FDA, as well as described how the profile of Ensysce's lead agent, PF614, checks all the categories of what could be perceived as an ideal pain product.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences, who moderated the symposium, commented, "Developing a novel opioid is not easy and we have been interested in sharing and discussing our technology with experts in the field who treat patients with pain on a daily basis. Our aim is to provide a new approach to treat severe pain with our novel class of opioid products that use our TAAP and MPAR platforms. These we believe will result in less abuse and overdose that have plagued traditional opioid products. We announced our plans to begin a Phase 3 pivotal trial shortly, as well as our intent to explore the use of PF614 in other indications such as cancer. Both trials are moving us one step closer to offering prescribers a new option to treat their patients more effectively."
The IASP has a mission to deliver pain relief throughout the world. Please find more information at the IASP website: https://www.iasp-pain.org.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on accesswire.com
FAQ
What new opioid products is Ensysce Biosciences (ENSC) developing?
When will Ensysce Biosciences (ENSC) begin Phase 3 trials for PF614?
What potential applications is Ensysce Biosciences (ENSC) exploring for PF614?
What government support has Ensysce Biosciences (ENSC) received for their opioid research?
